Microdose Tirzepatide: New Study Reports 4.4- to 6.9-Pound Average Weight Loss by Day 59

Retrospective analysis of 60 adults on compounded tirzepatide, 1-2 mg weekly: 4.4 lb average among 57 at days 14-35, 6.9 lb among 19 at days 36-59; not peer reviewed

ALPHARETTA, Ga., Sept. 21, 2026 (GLOBE NEWSWIRE) -- A newly posted PlexusDx preprint documents average self-reported body-weight loss of 2.2%, or 4.4 pounds, among 57 adults with eligible measurements during days 14-35 of treatment, at a median of 21 days. Among 19 patients with measurements during days 36-59, the average loss was 3.6%, or 6.9 pounds. The 60-patient analysis evaluated compounded injectable tirzepatide initiated at 1 or 2 mg per week, below the usual 2.5 mg weekly starting dose.

The retrospective study, posted on medRxiv Sept. 17, has not been peer reviewed. It had no comparison group and cannot establish that treatment caused the observed weight changes.

The PlexusDx study page provides a plain-language summary, charts and study limitations.